Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships
Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management. Dr. Scanlon also says that there is a lot of variation in the cost and quality of care in oncology. The goal is to identify the appropriate payments for quality care.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the treatment of prostate cancer with androgen-deprivation therapy and note that additional research is necessary to help determine which patient populations are at highest risk for developing resistance following ADT.
During this opening segment of a one-on-one interview series, Peter Salgo, MD, discusses emerging diagnostic and prognostic biomarkers in prostate cancer with Ira M. Klein, MD, MBA, FACP. Dr Klein discusses how results of ongoing trials will be useful to help identify biomarkers to help providers track disease progression.
The integrated cancer services offered by Sarah Cannon will soon be supported by the personalized medicine technology platform of Syapse, to improve individualized patient care, the companies have announced.
Clinical trials are critical for pushing the oncology field forward, but there is a need for not only more patients to participate in clinical trials, but for a more diverse population, said Howard K. Kaufman, MD, FACS.
Mobile health (mHealth) can be so much more than smartphone apps, and it is a growing movement in the United States that can empower patients, providers, and payers, according to Meg Maley, RN, BSN, founder and CEO of CanSurround.